Silex Systems (SLX) H2 2024 earnings summary

Executive summary

• Silex focuses on commercializing its SILEX laser enrichment technology for uranium, silicon, and medical isotope applications, with primary emphasis on uranium enrichment via Global Laser Enrichment (GLE).

• GLE is accelerating its full-scale pilot demonstration project, targeting completion by end of CY2024, and is preparing to bid for US Department of Energy (DOE) contracts following recent US legislation restricting Russian uranium imports.

• Silex is also advancing projects in quantum silicon production and medical isotope enrichment, supported by government and commercial partnerships.

• As of 30 June 2024, Silex holds $113.1m in cash and term deposits, with no corporate debt.

Financial highlights

• Cash and term deposit holdings stood at $113.1m as at 30 June 2024.

• No corporate debt reported as of the same date.

Outlook and guidance

• GLE aims to complete the TRL-6 pilot demonstration by end of CY2024, potentially enabling earlier commercial operations at the Paducah Laser Enrichment Facility (PLEF) than the original 2030 target.

• Silex expects to benefit from US government support, including $2.7bn in new nuclear fuel capacity funding and opportunities from the LEU Enrichment Acquisition RFP.

• The Quantum Silicon project is progressing toward initial commercial production, with government and industry funding.